Ipsen Licenses New Gout Drug to Menarini in €132M Deal
Ipsen SA has licensed rights to gout drug Adenuric - the first gout drug approved in four decades - in 41 countries to the Menarini Group in a deal that gives Ipsen €132 million (US$197 million).
Paris-based Ipsen will received €20 million up front, and retains co-marketing rights in France, where the companies will split market costs and profits, plus royalties in the low-teens on Menarini's net sales.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter